Cisplatin induces differentiation in teratomas derived from pluripotent stem cells

Autor: Masahiko Kuroda, Shin-ichiro Ohno, Atsushi Kurata, Koji Fujita, Masakatsu Takanashi
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Medicine (General)
ESC
embryonic stem cell
Adipose tissue
KSR
knockout serum replacement
0302 clinical medicine
ATP4B
ATPase H+/K+ transporting beta subunit
Induced pluripotent stem cell
DMEM
Dulbecco's modified Eagle's medium
HE
hematoxylin and eosin
LIF
leukemia inhibitory factor
RLU
relative light units
Induced pluripotent stem cells
medicine.anatomical_structure
ssDNA
single stranded DNA
Differentiation
RT
room temperature
Original Article
medicine.drug
iPSC
induced pluripotent stem cell
Embryonic stem cells
PCNA
proliferating cell nuclear antigen
Biomedical Engineering
Immature teratoma
Biology
α-SMA
α-smooth muscle actin
Biomaterials
Andrology
03 medical and health sciences
R5-920
PBS
phosphate buffered saline
Gastric mucosa
medicine
RAG
recombination activating gene
Cisplatin
CR
chemotherapeutic retroconversion
ALP
alkaline phosphatase
QH573-671
medicine.disease
Embryonic stem cell
MEF
mouse embryonic fibroblast
Transplantation
030104 developmental biology
FCS
fetal calf serum
Cytology
030217 neurology & neurosurgery
Immunostaining
Developmental Biology
Zdroj: Regenerative Therapy, Vol 18, Iss, Pp 117-126 (2021)
Regenerative Therapy
ISSN: 2352-3204
Popis: Introduction Currently, embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) can be induced to differentiate at the cellular level but not to form mature tissues or organs suitable for transplantation. ESCs/iPSCs form immature teratomas after injection into immunodeficient mice. In humans, immature teratomas often transform into fully differentiated mature teratomas after administration of anticancer agents. Methods We first investigated the ability of cisplatin to induce changes in mouse ESCs/iPSCs in vitro. Next, we designed experiments to analyze ESC/iPSC-derived immature teratoma tissue in vivo after treatment of cisplatin. Groups of six mice carrying ESC- or iPSC-derived teratomas were given either low or high dose intraperitoneal injection of cisplatin, while the control group received saline for 4 weeks. Results Treatment of ESC/iPSC cultures with cisplatin for 3 days caused a dose-related decrease in cell numbers without inducing any morphological changes to the cells. ESC/iPSC-derived teratomas showed lower growth rates with a significantly higher mature components ratio in a concentration dependent manner after cisplatin treatment (P
Highlights • Transformation of immature to mature teratoma after chemotherapy was verified. • Mice bearing ESC/iPSC-derived immature teratomas were used. • Mice were treated with intraperitoneal injection of cisplatin for 4 weeks. • Newly differentiated structures were found only in the tumors of treated mice. • Cisplatin can induce differentiation in ESC/iPSC-derived immature teratomas.
Databáze: OpenAIRE
Externí odkaz: